{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:03Z","timestamp":1790742003828,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":660,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670171"],"award-info":[{"award-number":["81670171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jtct.2021.05.006","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T14:44:17Z","timestamp":1621349057000},"page":"666.e1-666.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Moderate to Severe Marrow Fibrosis As a More Advanced Risk Factor for MDS and MDS-AML Patients With Excess of Blasts Receiving Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"27","author":[{"given":"Jiali","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.05.006_bib0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11912-015-0489-2","article-title":"Unraveling myelodysplastic syndromes: current knowledge and future directions","volume":"18","author":"Chamseddine","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jtct.2021.05.006_bib0002","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/bjh.16206","article-title":"How we manage adults with myelodysplastic syndrome","volume":"189","author":"Fenaux","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.05.006_bib0003","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2141.1991.tb04411.x","article-title":"Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity","volume":"78","author":"Lambertenghi-Deliliers","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.05.006_bib0004","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/modpathol.2013.187","article-title":"Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems","volume":"27","author":"Fu","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtct.2021.05.006_bib0005","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2405030","article-title":"Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes","volume":"22","author":"Buesche","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.05.006_bib0006","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.2147\/CMAR.S258875","article-title":"Patients of myelodysplastic syndrome with mild\/moderate myelofibrosis and a monosomal karyotype are independently associated with an adverse prognosis: long-term follow-up data","volume":"12","author":"Wang","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jtct.2021.05.006_bib0007","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3324\/haematol.2010.039875","article-title":"Myelodysplastic syndromes with bone marrow fibrosis","volume":"96","author":"Della Porta","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.05.006_bib0008","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","article-title":"Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R","volume":"123","author":"Della Porta","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.006_bib0009","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.05.006_bib0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbmt.2006.10.030","article-title":"Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia","volume":"13","author":"Scott","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.006_bib0011","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3324\/haematol.2010.031229","article-title":"Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis","volume":"96","author":"Kroger","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.05.006_bib0012","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.006_bib0013","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00277-013-1776-3","article-title":"The clinical importance of moderate\/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes","volume":"92","author":"Fu","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2021.05.006_bib0014","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.05.006_bib0015","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bbmt.2020.05.022","article-title":"Comparative study of mizoribine and mycophenolate mofetil combined with a calcineurin inhibitor-based immunosuppressive regimen in patients with alternative donor hematopoietic cell transplantation","volume":"26","author":"Huang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.006_bib0016","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-015-0182-9","article-title":"Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets","volume":"8","author":"Chang","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2021.05.006_bib0017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2141.1990.tb02612.x","article-title":"Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors","volume":"75","author":"Rios","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.05.006_bib0018","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s00277-018-3411-9","article-title":"Profile of fibrosis-related gene transcripts and megakaryocytic changes in the bone marrow of myelodysplastic syndromes with fibrosis","volume":"97","author":"Hussein","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2021.05.006_bib0019","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","article-title":"Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation","volume":"34","author":"Della Porta","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.05.006_bib0020","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/s41409-019-0444-1","article-title":"Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes","volume":"54","author":"Hamilton","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.006_bib0021","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.006_bib0022","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.006_bib0023","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23458","article-title":"Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome","volume":"88","author":"Alessandrino","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2021.05.006_bib0024","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.bbmt.2017.08.026","article-title":"Haploidentical hematopoietic stem cell transplantation for myelodysplastic syndrome","volume":"23","author":"Mo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.006_bib0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00277-013-1945-4","article-title":"Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis","volume":"93","author":"Machherndl-Spandl","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2021.05.006_bib0026","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1186\/1755-1536-5-S1-S25","article-title":"Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis","volume":"5","author":"Kroger","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.jtct.2021.05.006_bib0027","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/asheducation-2016.1.478","article-title":"Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens","volume":"2016","author":"Saber","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2021.05.006_bib0028","first-page":"1218","article-title":"Pre-transplant cytoreductive therapy can improve overall survival of patients with MDS-AML but not MDS-EB2 receiving HLA-matched sibling donor peripheral blood stem cell transplantation","volume":"10","author":"Wang","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jtct.2021.05.006_bib0029","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MOH.0000000000000217","article-title":"Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?","volume":"23","author":"Brierley","year":"2016","journal-title":"Curr Opin Hematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721008976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721008976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:00:57Z","timestamp":1763002857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721008976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2666636721008976"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.05.006","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moderate to Severe Marrow Fibrosis As a More Advanced Risk Factor for MDS and MDS-AML Patients With Excess of Blasts Receiving Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}